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Abstract
Aims We aimed to test whether the endogenous filtration markers serum creatinine or cystatin C and equation-based esti-
mates of glomerular filtration rate (GFR) based on these markers appropriately reflect changes of measured GFR in patients
with acute heart failure.
Methods In this prospective cohort study of 50 hospitalized acute heart failure patients undergoing decongestive therapy,
we applied an intravenous visible fluorescent injectate (VFI), consisting of a low molecular weight component to measure
GFR and a high molecular weight component to correct for measured plasma volume. Thirty-eight patients had two sequential
GFR measurements 48 h apart. The co-primary endpoints of the study were safety of VFI and plasma stability of the high
molecular weight component. A key secondary endpoint was to compare changes in measured GFR (mGFR) to changes of
serum creatinine, cystatin C and estimated GFR.
Results VFI-based GFR measurements were safe and consistent with plasma stability of the high molecular weight compo-
nent and glomerular filtration of the low molecular weight component. Filtration marker-based point estimates of GFR, when
compared with mGFR, provided only moderate correlation (Pearson’s r, range 0.80–0.88, depending on equation used), pre-
cision (r2, range 0.65–0.78) and accuracy (56%–74% of estimates scored within 30% of mGFR). Correlations of 48-h changes
GFR estimates and changes of mGFR were significant (P < 0.05) but weak (Pearson’s r, range 0.35–0.39). Observed decreases
of eGFR by more than 15% had a low sensitivity (range 38%–46%, depending on equation used) in detecting true worsening
mGFR, defined by a >15% decrease in mGFR.
Conclusions In patients hospitalized for acute heart failure, serum creatinine- and cystatin C-based predictions performed
poorly in detecting actual changes of GFR. These data challenge current clinical strategies to evaluate dynamics of kidney func-
tion in acute heart failure.
Keywords Acute heart failure; Worsening kidney function; Acute kidney injury; CKD-EPI formula; Measured GFR; Visible fluorescent
injectate
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Introduction
The kidney’s glomerular filtration rate (GFR) critically contrib-
utes to heart failure pathophysiology1,2 and is generally
closely monitored in patients undergoing decongestive ther-
apy for acute heart failure (AHF), usually by measuring serial
serum creatinine (SCr) concentrations or less frequently by
measuring serum cystatin C (CysC) concentrations. Increases
in SCr and CysC in AHF patients are usually considered an om-
inous sign of ‘worsening renal function’ (WRF). Definitions of
WRF based on these markers have been labelled as risk
factors or primary endpoints in heart failure studies.3–7 A
growing body of evidence, however, indicates that changes
of SCr or CysC suggesting worsening GFR are neither closely
associated with structural tubular injury nor with adverse
outcomes in patients with AHF undergoing decongestive
therapy, especially when accompanied by evidence of effi-
cient decongestion, diuresis and hemoconcentration.8–12
It has been demonstrated in stable chronic heart failure
populations that formula-based point estimates of GFR
(eGFR) have a relatively poor precision and accuracy in
predicting measured GFR (mGFR).13–15 This may be further
aggravated in the setting of AHF, where extracellular fluid ex-
pansion and volume shifts under intensified decongestive
therapy may lead to (1) dynamic alterations of GFR that un-
dermine the steady-state assumptions of GFR-estimating
equations or (2) dilution or concentration of SCr and CysC
independent from GFR alterations.
Established equations frequently applied in clinical practice
to determine eGFR based on SCr and/or CysC, age, gender
and ethnicity were developed in individuals with stable
steady-state equilibrium of kidney function. They include the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations16 and the Modification of Diet in Renal Disease
Study (MDRD) equation17 (see Table S1 for details). In
addition, a kinetic eGFR equation (keGFR) has been proposed
when SCr concentrations are not in steady-state equilibrium.18
Whether SCr, CysC or filtration marker-based equations accu-
rately reflect GFR and its dynamic changes in patients with
AHF is unknown, because studies of point or serial measure-
ments of actual GFR in AHF patients have not been conducted.
Nevertheless, clinicians will usually consider SCr or CysC as
surrogates of GFR in AHF patients and may apply eGFR equa-
tions, even under non-steady-state conditions. The term
‘worsened renal function’ is not uniformly defined in the
heart failure field and usually refers to a percentage decrease
of estimated GFR based on SCr and/or CysC19 or to an
absolute or relative increase of SCr as utilized in the KDIGO
definition of acute kidney injury (AKI).20 For instance, the re-
cent ROSE-AHF trial defined WRF as a 20% decrease of eGFR
based on the CKD-EPI equation, which utilizes SCr and CysC.8
Misjudgements of GFR trajectories in the context of AHF
may affect therapeutic decision making. For instance, a
diagnosis of creatinine-based worsening GFR may prompt
premature discontinuation of aggressive diuresis or even con-
tribute to volume administration or the initiation of kidney
replacement therapy. In addition, pharmacological heart fail-
ure therapy with renin–angiotensin system blockers may be
withheld, if worsening GFR is assumed to be present. In con-
trast, a failure to diagnose true worsening of GFR in these
subjects may lead to prolonged structural kidney injury,
resulting in chronic kidney disease (CKD) progression.21–23
Data regarding the changes of actual GFR during heart fail-
ure therapy are currently lacking. To address this knowledge
gap, we conducted a clinical study in patients undergoing de-
congestive therapy for AHF and utilized a recently developed
fluorescent tracer-based method24 to rapidly measure GFR at
two consecutive time points during heart failure therapy. We
assessed safety and functionality of the fluorescent tracer-
based method and compared mGFR to SCr- and CysC-based
estimates of GFR and different definitions of worsening GFR.
Methods
Population
This prospective multicentric Phase 2b study was performed
at the Nephrology and Cardiology Departments of Charité –
Universitätsmedizin Berlin and at the Cardiology Department
of Kerckhoff Klinik, Bad Nauheim, between January and July
2019. Fifty patients undergoing either intravenous or oral de-
congestive diuretic therapy for AHF were enrolled following
written informed consent. Eligible participants had to have
a diagnosis of AHF and were aged ≥18 years with evidence
of AHF based on presence of ≥1 symptom (dyspnoea,
orthopnoea or oedema) and ≥1 sign (rales, peripheral
oedema, ascites or pulmonary vascular congestion on chest
radiography).25 Exclusion criteria included pregnancy, acute
onset of myocardial infarction, unstable angina pectoris,
new onset of atrial fibrillation, requirement of intravenous
vasodilators or inotropic agents, acute or chronic need for re-
nal replacement therapy, significant non-cardiac diseases, se-
vere infections and internal bleeding. Non-sterile participants
agreed to use effective methods of contraception.
Data were handled in respect of patient anonymity and
confidentiality. The study was approved by the regional ethics
board Berlin and conducted in accordance with Declaration
of Helsinki guidelines (EduraCT Number 2018-002638-18,
https://clinicaltrials.gov/ct2/show/NCT03808948).
Measurement of GFR
mGFR was determined by measuring the plasma clearance of
an intravenously injected fluorescently labelled dextran,
which is freely filtered by the glomerulus and not reabsorbed
into the blood. The visible fluorescent injectate (VFI) (FAST
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BioMedical, Indianapolis, IN, USA), consists of 12 mg of a
150-kDa carboxymethylated dextran, conjugated to a rhoda-
mine dye (FD003), and 35 mg of a 5-kDa carboxymethylated
dextran, conjugated to fluorescein (FD001).
A volume of 3.0 mL was infused intravenously. Blood sam-
ples were collected right before and 15, 30, 60 and 180 min
after injection. Blood plasma was run on a validated
BioAnalytical HPLC assay at Covance Laboratories in Salt Lake
City, Utah. Plasma volume (PV) was determined using the av-
erage FD003 concentrations of the early 15 and the 60 min
time point. The low molecular weight dextran is freely fil-
tered, consistent with inulin.26 mGFR determined by VFI
technology has been shown to be nearly identical to mGFR
determined by a 6-h iohexol protocol (considered a gold
standard in the field) in normal subjects and subjects with
CKD.24 The concentration of the small dextran GFR marker
at time zero was back-calculated from the measured PV by
dividing the known dose into the measured PV. The time
points were then fitted using a two-compartment model,
and the resulting area under the curve was calculated. The
use of the time point 0 determination helped to better re-
solve the shape of the clearance curve. mGFR was calculated
and adjusted to body surface area as described previously.
The FAST patented software technology only reports an
mGFR value for assays where the four-point clearance curve
yields a valid two-exponent data fit, where both rates are
positive and conform to the expected fast and slow decay
profiles.
Study design
GFR was measured in the morning after enrollment (Fay 1)
and 48 ± 5 h after the first measurement (Day 3, whenever
feasible). Body weight and height were determined, and ve-
nous blood was drawn to determine SCr (Jaffé, IDMS stan-
dardized) and CysC (immunoturbidimetry) before injection
of the fluorescent tracer. mGFR results were not available
to treating physicians. Subjects were followed for 30 days af-
ter the last VFI injection and assessed for adverse and serious
adverse events.
The co-primary endpoints of the study were the assess-
ment of safety of VFI (the safety endpoint was predefined
as an absence of compound-related treatment-emergent se-
vere adverse events) and the confirmation of plasma stability
of the FD003 high molecular weight marker over the 15-, 30-,
and 60-min blood draws (defined as differences < 10% of
mean plasma concentrations of FD003 between time points
15 and 30 min and between time points 30 and 60 min, re-
spectively). No formal hypothesis test was used to calculate
the sample size. The sample size was set to 50 patients, which
was deemed adequate, given the primary endpoints were
consistent with those of a Phase 2 study. The comparison of
GFRs determined by VFI mGFR technology with estimated
GFR using established equations was a predefined secondary
endpoint. The authors had full access to the data and take full
responsibility for its integrity. All authors have read and agree
to the manuscript as written.
Equations estimating GFR and definitions of
worsening GFR
Five equations were used as SCr- and CysC- based estima-




16 and kinetic eGFR.18 Table S1
shows these equations in detail. True worsening mGFR was
diagnosed when changes in mGFR from Day 1 to Day 3
indicated an mGFR decrease > 15%. KDIGO criteria for AKI
are based on changes of SCr (e.g. Stage 1 is defined by an
increase of SCr by <0.3 mg/dL or an increase of SCr by
1.5-fold).28 To assess whether a change of mGFR (as measured
by serial VFI measurements) was equivalent to AKI, we used
mGFR and back-calculated hypothetical idealized SCr values
when applying a reverse CKD-EPISCr equation (see Supporting
Information). This allowed us to make an mGFR-based ‘true
AKI’ diagnosis, which was then compared with the actual
SCr-based AKI definition.
Statistical analysis
Descriptive analyses were done by reporting the quantiles of
the empirical distributions of the respective variables, for ex-
ample, mean and standard deviation for continuous data,
median and interquartile range for skewed distributed data
and frequencies with percentages for categorical variables.
Student’s t-test was used to compare continuous variables.
For known skewed data, the Mann–Whitney U test was used.
The Wilcoxon test was used to compare dependent samples
for continuous variables. Chi-square tests were used to
compare independent categorical variables.
Correlations between mGFR and eGFR using different GFR
estimation equations and correlations between percentage
changes in mGFR and eGFR were provided using Pearson’s
correlation coefficients. The predictive performance of the
equations was evaluated by precision, accuracy and bias. Pre-
cision was evaluated by the amount of expected variation in
the estimates using linear regression and reporting r2. Accu-
racy was assessed by comparing the results of eGFR with
those of mGFR and counting the number of subjects with pre-
dicted eGFR values within the 15% (P15) and 30% (P30) range
of mGFR. Bias was defined as mean difference of the esti-
mated and measured value. Further, 95% confidence intervals
(CI) and standard deviation were calculated where appropri-
ate. Agreements between measured and estimated GFR were
assessed with Bland–Altman plots. Predefined limits of agree-
ment were set to ±6 mL per min per 1.73 m2 based on clinical
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considerations in AHF patients, who often exhibit pre-existing
CKD. In CKD Stage G3A, G3B or G4, differences of eGFR and
mGFR that are more than 6 mL/min would place >40% of pa-
tients into different GFR stages, which might have clinically
meaningful implications.
The statistical analysis was performed with the use of SPSS
(Chicago) Version 23, GraphPad Prism Version 8 and R Core
Team (2018, R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria). All reported P-values are two tailed. Due to the
exploratory character of the study, all reported results and
P-values have to be considered as non-confirmatory.
Results
Patient characteristics and outcomes
We enrolled 50 hospitalized patients with AHF undergoing
diuretic decongestive therapy, which included at least an
intravenous loop diuretic in 40 patients (80%) and at least
an oral loop diuretic in 10 patients (20%). Baseline character-
istics are shown in Table 1.
mGFR was determined using VFI technology 2 days
(median; IQR 1–3 days) after hospital admission (Day 1 of
the study). A second GFR measurement was performed
Table 1 Baseline characteristics of the cohort at enrollment (Day 1)
All patients Patients with two GFR measurements 48 h apart
50 38
Demographic data
Age (years) 72.5 ± 13.7 71.9 ± 14.4
Male 40(80) 29(76.3)
Caucasian 48(96) 36(94.7)
Clinical data at enrolment
Weight (kg) 89.2 ± 22.2 89.8 ± 23.2
Height (cm) 172.8 ± 10.6 172.1 ± 11.7
BMI (kg/m2) 29.7 ± 6 30.1 ± 5.8
Systolic blood pressure (mmHg) 126 ± 23.6 126.3 ± 24.7
Diastolic blood pressure (mmHg) 71.6 ± 14.1 71.7 ± 15.1
Mean arterial pressure (mmHg) 89.8 ± 14.2 89.9 ± 14.9
Heart rate (bpm) 73.5 ± 15.8 76 ± 13.6
NYHA Class II 7 (14) 4(10.5)
NYHA Classes III–IV 43 (86) 34(89)
LVEF (%) 47.9 ± 15.5b 46 ± 14.8c





Coronary artery disease 31(62) 25(65.8)
Hypertension 46(92) 35(92.1)
Peripheral arterial occlusive disease 10(20) 7(18.4)
Baseline eGFR (CKD-EPISCr) (mL per min per 1.73 m
2) 49.8 ± 21.2 50.1 ± 21.2
CKD-Stage 1–2 21(42) 16(42)
CKD-Stage ≥3 29(58) 22(58)
Medication at enrolment
RAASI 36 (72) 28(73.7)
Loop diuretic 50 (100) 38(100)
Thiazide diuretic 8 (16) 6(15.8)
Aldosterone antagonist 19(38) 15(39.5)
β-Blocker 37 (74) 29(76.3)
Laboratory values at enrolment
SCr (mg/dL) 1.8(1.3–2.1) 1.8(1.2–2.2)
CysC (mg/L) 2.2(1.6–2.7) 2.2(1.7–2.5)
NT-proBNP (ng/L) 3737(1822–7427)a 3647(1830–8076.5)b
Haematocrit, (%) 34.3(30.2–40)c 34.3(30–39.7)c
Data are presented as mean ± standard deviation, median (interquartile range) or number (percentage), as appropriate. No statistically
significant differences between patients with two GFR measurements, and patients with one GFR measurement only were noted except
for heart rate (P, Student’s t-test, Mann–Whitney U test, chi-square test, as appropriate). Data are rounded to one decimal place; missing
data are indicated by superscript letters.
BMI, body mass index; CKD, chronic kidney disease; Cys C, cystatin C; GFRBaseline, eGFR CKD-EPISCr based on the clinically adjudicated out-
patient baseline creatinine; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RAASI, re-
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48 h later in 38/50 (76%) patients (Day 3 of the study). VFI
consists of two components, a high molecular weight compo-
nent (FD003) and a low molecular weight component
(FD001). Following VFI injection, FD003 is retained in the in-
travascular space, whereas FD001 is freely filtered by the glo-
merulus. Blood draws were obtained 15, 30, 60 and 180 min
after VFI injection to determine plasma concentrations of
FD001 and FD003. PV was calculated from the plasma con-
centration of FD003 based on the indicator dilution principle.
The starting concentration of FD001 was calculated based on
the PV, and measured FD001 kinetics over the following
180 min were fitted to calculate mGFR.
The first co-primary endpoint of this study was safety.
Twenty-one (42%) patients had treatment-emergent
severe adverse events (including one death and four
rehospitalizations) in this AHF population, but all were con-
sidered typical in AHF setting and unrelated to the VFI com-
pound. This indicated that the predefined primary safety
endpoint of the study was met. There were 37 patients
(74%) with a total of 177 treatment-emergent adverse events
(TEAEs). One hundred sixty-four TEAEs were considered not
related or unlikely related to VFI. Thirteen TEAEs of 10 pa-
tients (20%) were considered to be possibly, probably or
surely related to study drug (Table S2). These included diar-
rhoea (one moderate, three mild), hypersensitivity or pruritus
(two moderate, one mild), vertigo (one mild) and laboratory
abnormalities (five mild). Two patients were discontinued
due to urticaria and pruritus after VFI administration. These
symptoms resolved quickly with administration of antihista-
mine therapy.
The second co-primary endpoint of this study was stability
of FD003 within the intravascular compartment, which is con-
sidered to be a critical prerequisite for calculating PV. The
concentration of FD003 was stable throughout the sampling
period. Differences of mean plasma concentrations of
FD003 between time points 15 and 30 min (2.36 ± 7.94%
on Day 1 and 3.12 ± 11.29% on Day 3) and between time
points 30 and 60 min (0.8 ± 5.6% on Day 1 and
0.79 ± 8.67% on Day 3) were below the pre-specified 10%
margin. A small subset of patients showed a >10% decline
in the concentration of FD003, but these declines were re-
stricted to individual time points per patient and did not
show a systematic decline over time in any individual. The ob-
served plasma stability indicates that FD003 follows the indi-
cator dilution principle in acute decompensated heart failure
patients. Kinetics of FD001 were compatible with elimination
kinetics by glomerular filtration in all 50 patients.
Static relationships of creatinine- and cystatin
C-based GFR estimates and mGFR
We first compared eGFR calculated on Day 1 according to five
established equations (sMDRD, CKD-EPISCr, CKD-EPICysC, CKD-
EPISCr-CysC and keGFR) to mGFR determined on the same
day (Tables 2 and S3). Mean eGFRs according to sMDRD,
CKD-EPISCr and keGFR were significantly higher when com-
pared with mean mGFR, whereas mean eGFR according to
CKD-EPICysC on Day 1 was significantly lower than mGFR.
CKD-EPISCr-CysC did not differ significantly from mGFR. Similar
results were observed on day 3 (Table S3 and Figures S1 and
S2). None of the equations met predefined limits of agree-
ment of ±6 mL per min per 1.73 m2. Bland–Altman plots indi-
cated that all equations tended to underestimate mGFR in
the low GFR range (<40 mL per min per 1.73 m2) and overes-
timate GFR in the high GFR range (>40 mL per min per
1.73 m2) (Figure S3).
The overall performance of formula-based estimates of
mGFR was evaluated by analysing correlation (Pearson’s r),
precision (r2), accuracy (P15, P30) and bias (Tables 2 and S4).
Filtration marker-based estimates of GFR at any given time,
when compared with mGFR, provided only moderate
correlation (Pearson’s r, range 0.80–0.88, depending on
equation used), precision (r2, range 0.65–0.78) and accuracy
(56%–74% of estimates scored within 30% of mGFR).
To analyse determinants of systematic error, we evaluated
the predictive performance of the equations by subgroups.
Age significantly affected bias of CKD-EPICysC and CKD-EPISCr-
CysC. Endogenous marker concentrations strongly affected
bias of all equations with lower SCr and CysC, leading to
Table 2 Performance of SCr- and CysC-based equations when compared with measured GFR in AHF patients at enrollment (Day 1)
Mean ± SD Bias mean ± SD Pearson’s r Precision
Accuracy
r r2 P15 P30
mGFR (mL per min per 1.73 m2) 35 ± 11.7
sMDRD (mL per min per 1.73 m2) 40.4 ± 17.1* 5.4 ± 10.2 0.81 0.66 40% 70%
CKD-EPISCr (mL per min per 1.73 m
2) 40.4 ± 18.5* 5.4 ± 11.3 0.81 0.66 40% 66%
CKD-EPICysC (mL per min per 1.73 m
2) 31 ± 16.6* 4.0 ± 9.9 0.81 0.66 40% 56%
CKD-EPISCr-CysC (mL per min per 1.73 m
2) 34.6 ± 17 0.4 ± 9.6 0.84 0.70 30% 74%
keGFR (mL per min per 1.73 m2) 41.4 ± 18* 6.6 ± 11.7 0.80 0.65 26% 66%
Accuracy P15 and P30 refers to per cent of GFR estimates that are within 15% and 30% of measured GFR, respectively. GFR data and bias
are presented as mL/min/1.73 m2.
SD = standard deviation.
*P < 0.01 vs. MGFR.
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marked overestimation of mGFR by sMDRD, CKD-EPISCr and
keGFR, whereas higher SCr and CysC concentrations were as-
sociated with underestimation of GFR by CKD-EPICysC and
CKD-EPISCr-CysC (Table 3).
Comparison of relative changes of serum
creatinine and serum cystatin C and
corresponding changes of mGFR
The repeat measurement design of our study enabled us to
assess relative changes of mGFR between Day 1 and day 3
and compare them to changes of SCr, CysC and GFR estimates.
We analysed the 48-h changes of mGFR and the correspond-
ing changes of eGFR in individual study patients. The data
indicated that the change of eGFR provided profoundly
inadequate estimates of the true mGFR trajectory in a subset
of AHF patients (Figure 1). Correlation coefficients of 48-h
changes of GFR estimating formulas and corresponding
changes of mGFR indicated weak, but significant correlations
(Pearson’s r, range 0.35–0.39, depending on equation used)
(Figure S4). A statistically significant but weak negative
correlation was observed between 48-h changes in CysC and
corresponding 48-h changes of mGFR (r = 0.37, P = 0.022),
whereas SCr changes did not correlate significantly with 48-
h changes of mGFR (r = 0.31, P = 0.057) (Figure S5).
Observed decreases of eGFR by more than 15% had a low sen-
sitivity (range 38%–46%, depending on equation used) in de-
tecting true worsening mGFR, defined by a >15% decrease
in mGFR (Figure 2 and Table 4). Similarly, KDIGO creatinine
criteria for AKI had a poor sensitivity in detecting correspond-
ing decreases of mGFR (Figure 2 and Table 4). Changes of Scr,
CysC and eGFR from Day 1 to Day 3 frequently provided
false-negative signals in patients with declines of mGFR and
occasionally triggered false-positive signals (Figure 2). Accord-
ingly, trajectories of SCr, CysC and eGFR from Day 1 to Day 3 in
individuals with a true worsening mGFR > 15% frequently
failed to reveal corresponding increases in filtration markers
and decreases of eGFR (Figure 3). Conversely, patients with
stable or increasing mGFR occasionally exhibited erroneous
increases of filtration markers providing false-positive signals.
Hence, definitions of ‘worsening kidney function’ based on
the serial application of eGFR equations or based on KDIGO
AKI criteria had weak test characteristics, in particular a poor
sensitivity, in detecting worsening mGFR in AHF patients.
Discussion
Key findings and novelty
To our knowledge, this is the first study comparing estimates
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measurements by the VFI technology established safety and
functionality of this technique in AHF and enabled us
to evaluate changes of mGFR over time and analyse the
dynamic performance of filtration markers and filtration
marker-derived GFR estimating equations and comparison
vs. definitions of ‘worsening renal function’ or ‘AKI’. The key
finding of this study is that time courses of SCr, CysC or eGFR
(by any formula) provide insufficient information regarding
the time course of mGFR and have limited sensitivity in
detecting true worsening GFR.
Functionality and safety of VFI technique
Previous techniques for GFR measurements, such as inulin,
iothalamate or iohexol clearance, are time consuming
(>5 h), making them less suitable in the setting of worsening
GFR.29 In contrast, the VFI-based technique used in this study
allows determination of the clearance rate constant based on
a low molecular labelled dextran and PV based on a high mo-
lecular weight dextran, allowing accurate GFR calculation
within a relatively short time window of 180 min and facilitat-
ing repeat GFR measurements.24 In the current study, plasma
kinetics of the low molecular labelled dextran were compati-
ble with glomerular filtration, whereas the high molecular
weight dextran was stably retained in the plasma compart-
ment. The VFI technique for GFR measurement has been val-
idated against iohexol GFR measurements,24 a widely
accepted standard technique for GFR assessment.30 Using
the VFI technique as comparator in healthy subjects and
CKD patients, the CKD-EPIScr-derived eGFR had a high accu-
racy (P30 90.6%) and precision (r
2 0.92) and an acceptably
small systemic error of 4.4 mL per min per1,73 m2 in
predicting mGFR.24 The first co-primary endpoint of this
study was safety, and for this purpose, adverse events were
analysed. Though no severe adverse events were considered
related to the VFI compound, a subset of patients exhibited
mild or moderate events suggestive of allergic reactions, in-
cluding two cases of transient pruritus and urticaria, which
resolved within 30–60 min after antihistamine treatment. A
previously published study using VFI reported no serious ad-
verse events.24,31 Placebo-controlled data on the VFI com-
pound are currently limited to one small Phase 1 study, in
which VFI or placebo was administered in 32 healthy sub-
jects. TEAEs were recorded in 15/24 patients in the VFI group
(63%) and in 7/8 patients in the placebo group (88%). None
of these adverse events was severe, and the high
percentage of events in the placebo group reflects the mild
nature of the adverse events.
Performance of static GFR estimates based on
filtration markers in AHF patients
The KDIGO Clinical Practice Guideline for the Evaluation and
Management of Chronic Kidney Disease 201232 recommends
to report GFR estimates that have a comparable or better ac-
curacy (P30) than CKD-EPISCr (2009),
27 CKD-EPICysC (2012) and
CKD-EPI SCr-CysC (2012) (P30 87.2%, 85.9% and 91.5%,
respectively16). The National Kidney Foundation (NKF) recom-
mends an accuracy performance of at least 75% to be consid-
ered in clinical decisions and advises against the use of GFR
equations that do not meet this margin as tools in clinical de-
cision making.33,34 In our AHF cohort, we observed accuracies
(P30) between 56% and 74%, depending on the equation. No-
tably, the most frequently applied CKD-EPIScr and sMDRD
equations, which rely solely on SCr as a filtration marker, pro-
vided P30 values of only 63%–66% and 66%–70%, respec-
tively, which are markedly below recommended thresholds.
Among all equations, the CKD-EPIScr-CysC provided the highest
Figure 1 Individual patient data of 48 hour changes in mGFR and corresponding changes in eGFR based on CKD-EPISCr, CKD-EPICys, CKD-EPISCr-Cys,
sMDRD and keGFR. Patients are sorted by direction and intensity of the change in mGFR during the 48-h study period. Please note that several patients
(e.g. Patients 1, 2, 17, 31, 35 and 36) display a substantial mismatch between the formula-based estimated change of GFR and the true change of mea-
sured GFR.
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(but still suboptimal) accuracy (P30) of 71%–74%. Whereas no
previous study had evaluated mGFR in AHF patients, several
previous studies have assessed mGFR in chronic heart failure
patients.13–15 Published accuracies (P30) for different eGFR
equations in these patients range from 58% to 89%.13–15 To-
gether, these data suggest that filtration markers have limited
performance in heart failure patients in general, but become
even less valid in AHF.
Performance of filtration markers in dynamically
assessing WRF in AHF patients
Changes of SCr or CysC over time are used to diagnose ‘wors-
ening renal function’ or ‘AKI’ according to widely accepted
criteria in and outside the heart failure literature.3,19,28,35,36
Though it is presumed that increases of SCr or CysC indicate
Figure 2 Changes in mGFR and corresponding changes in SCr and GFR estimates. (A) The difference in SCrDay1  SCrDay3 (in mg/dL), which is used for
the KDIGO AKI definition (increase ≥0.3 mg/dL within 48 h indicates Stage 1 AKI), is plotted against ‘the change of back-calculated creatinine’, that is,
the idealized hypothetical SCr values that would have corresponded to mGFRDay1 and mGFRDay3 based on reverse application of the CKD-EPISCr equa-
tion (for details, see Methods section). (B–F) The percent differences of eGFRDay3  eGFRDay1 (B) CKD-EPIScr, (C) CKD-EPICysC, (D) CKD-EPIScr-CysC, (E)
sMDRD and (F) keGFR are plotted against the per cent differences in mGFRDay3  mGFRDay1. Green area represents agreement of AKI diagnosis or
GFR loss based on eGFR and mGFR, as appropriate. Red-striped area represents mismatch of AKI diagnosis or GFR loss based on eGFR and mGFR,
as appropriate.
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decreasing GFR, no studies with serial mGFR assessments are
available to date.
In this study of AHF patients, we found that the dynamic
changes of SCr, CysC and eGFRs estimated with several equa-
tions provided poor estimates of the actual mGFR time
course. In addition, the presumptive decline in GFR underly-
ing KDIGO SCr-based AKI criteria weakly correlated to
changes of mGFR. Endogenous filtration markers like SCr or
CysC require steady-state conditions to provide proper esti-
mates of GFR.37 Kinetic eGFR calculated based on SCr
Table 4 Test characteristics of KDIGO AKI creatinine criteria and of eGFR-based definitions of ‘worsening renal function’ in predicting true
GFR loss





55% (23–83%) 93% (76–99%) 83% (65–94%) 75% (35–97%) 7.4 (1.7–31) 0.5 (0.3–0.9)
>15% eGFR sMDRD
loss predicting >15% mGFR loss
46% (19–75%) 92% (74–99%) 77% (58–90%) 75% (35–97%) 5.8 (1.3–24.7) 0.6 (0.3–1)
>15% eGFR CKD-EPISCr
loss predicting >15% mGFR loss
46% (19–75%) 92% (74–99%) 77% (58–90%) 75% (35–97%) 5.8 (1.3–24.7) 0.6 (0.3–1)
>15% eGFR CKD-EPICysC
loss predicting >15% mGFR loss
46% (19–75%) 84% (64–96%) 75% (55–89%) 60% (26% – 88) 2.9 (0.9–8.4) 0.6 (0.4–1.1)
>15% eGFR CKD-EPISCr-CysC
loss predicting >15% mGFR loss
46% (19–75%) 92% (74–99%) 77% (58% – 90%) 75% (35% – 97%) 5.8 (1.3–24.7) 0.6 (0.3–1)
>15% keGFR loss predicting
>15% mGFR loss
38% (14–68%) 92% (74–99%) 74% (55–88%) 71% (29–96%) 4.8 (1.1–21.5) 0.7 (0.4 – 1)
Data are presented as estimates (95% CI) and rounded to the nearest integer.
+LR, positive likelihood ratio; LR, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
Figure 3 Time courses of SCr (D–F), CysC (G–I) and different GFR estimates: sMDRD (J–L), CKD-EPISCr (M–O), CKD-EPICys (P–R), CKD-EPISCrCys (S–U),
keGFR (V–X) in patients with stable mGFR (difference of mGFRDay3-mGFRDay1 > 15% and < +15%; n = 21 (A)), true decrease of (difference of mGFR-
Day3  mGFRDay1 ≤ 15%; n = 13 (B)) and true increase of mGFR (difference of mGFRDay3  mGFRDay1 ≥ +15%; n = 4 (C)) within 48 h.
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dynamics was previously proposed to provide a more
accurate account for acute changes of SCr levels based on
mathematical models,18 but it has not been validated against
GFR measurements. Here, we show that keGFR did not sub-
stantially outperform other eGFR equations both as a static
GFR estimate and as an estimate of GFR changes over time.
These observations indicate that GFR-independent deter-
minants of SCr and CysC influence their blood levels and
therefore contribute to the weak performance of eGFR equa-
tions in AHF. Sarcopenia, immobilization and cardiac cachexia
in heart failure patients may contribute to reduced creatinine
production frommuscle tissue.38–40 CysC is considered largely
independent of muscle wasting and sarcopenia, but an associ-
ation between elevated CysC levels and higher fat mass has
been described.41 The lower muscle mass and higher fat
percentage in elderly heart failure patients could partially
explain the observed averaged underestimation of mGFR by
CKD-EPICysC and overestimation by CKD-EPISCr. In addition,
the expansion of extracellular space in AHF patients enlarges
the volume of distribution of creatinine, thereby potentially
lowering SCr and Cys C concentration. Conversely, quick
contractions of extracellular fluid during decongestive therapy
may lead to GFR-independent increases of SCr and CysC levels.
There is evidence that increased CysC levels are associated
with risk of cardiovascular diseases42 and CKD-EPICysC has
been shown to have a better predictive value for adverse out-
comes in AHF patients than CKD-EPISCr or CKD-EPIScr-CysC.
43
Consistently, in our cohort, we observed a more accurate,
but still imperfect, reflection of mGFR changes by CysC.
Clinical impact
During clinical management in AHF, the detection of eGFR
decreases will often trigger important clinical decisions. How-
ever, our study shows that SCr has limited value in identifying
decreasing or increasing GFR in AHF patients. This may result
in inappropriate dose adjustments of medications, including
renin–angiotensin–aldosterone (RAAS) inhibitors and di-
uretics, deferral of procedures involving contrast agents or
discontinuation of potentially nephrotoxic drugs. In addition,
a failure to detect true worsening GFR in these subjects
may lead to prolonged kidney injury, resulting in CKD
progression.44,45 Detecting an increasing GFR based on SCr
reductions is often viewed as a sign of therapeutic success,
but our data suggest that a decrease of SCr may not always
be accompanied by corresponding increases of mGFR. Hence,
the limitations of SCr in AHF need to be considered clinically.
To date, the ability to measure GFR in a timely fashion that
would influence clinical decision making has not been possi-
ble. Therefore, the potential impact of mGFR on clinical deci-
sion making is unknown. However, a multitude of studies
assessed the prognostic value of rises in SCr or CysC or de-
creases of eGFR (defined as ‘worsening renal function’)
during decongestive therapy. But neither rise in SCr nor
increase in tubular injury biomarkers was found to be associ-
ated with post-discharge adverse outcomes.8,46 Our data sug-
gest that ‘worsening renal function’ in these studies may not
necessarily have been a reflection of true worsening of
mGFR. Hence, the prognostic impact of true GFR loss in
AHF should be evaluated in order to assess the relationship
between actual functional loss and adverse outcomes. It is
likely that knowing the dynamics of mGFR during therapy
for AHF patients will result in more complete, effective and
safe clinical decisions.
Study limitations
Our study has limitations. First, our cohort of patients with AHF
was predominantly male and almost exclusively Caucasian. Be-
cause patients in intensive care units receiving i.v. vasodilators
and inotropics were excluded, the results of this study cannot
be generalized to these subsets of heart failure patients.
Second, the sample size of the study was relatively small
(50 patients) and repeat GFR assessments (Day 3) were only
available in a sub-cohort (38 patients). Third, though all pa-
tients enrolled into the study were undergoing decongestive
therapy for AHF, the timing of mGFR assessments varied rela-
tive to hospital admission. Fourth, intensity and duration of
diuretic therapy were not standardized. Hence, the serial GFR
measurements within a 48-h window provided a snapshot of
GFR dynamics but did not reflect the GFR trend of the whole
decongestive treatment process. Finally, the cohort was rather
heterogeneous with regard to baseline characteristics and
included both HFrEF and HFpEF patients with ischaemic and
non-ischaemic causes. The different degree of neurohumoral
activity, patterns of cardiac remodelling, and differential
response to drug therapies suggest that HFpEF and HFrEF are
two distinct disease processes.47,48 Our studywas not powered
to investigate the influence of HF type on mGFR trajectories.
Conclusion
In this prospective study of patients with AHF undergoing
decongestive therapy, we found that frequently used clinical
estimates of GFR based on the filtration markers Scr and CysC
failed to meet previously recommended margins of accuracy
and precision. Most importantly, changes of filtration markers
and their derived GFR estimates frequently failed to detect
true worsening of mGFR. Our findings highlight the limitations
of filtrationmarkers to evaluate dynamics of kidney function in
patients with AHF and suggest that caution should be applied
when using these markers to guide clinical decision making.
Measuring GFR directly using minimally invasive techniques,
such as the VFI technique utilized here, could provide a practi-
cal alternative to ensure accurate monitoring of GFR.
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